{
    "ticker": "SVRA",
    "name": "Savara Inc.",
    "description": "Savara Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for patients with rare respiratory diseases. Established in 2017, Savara has been dedicated to improving the lives of patients through the advancement of inhaled therapies that target unmet medical needs. The company's lead product candidate, Molgradex, is in late-stage clinical development for the treatment of pulmonary alveolar proteinosis (PAP), a rare and serious lung disease that can lead to respiratory failure. Savara's approach leverages its proprietary inhalation technology to deliver treatments directly to the lungs, enhancing efficacy and minimizing systemic side effects. In addition to Molgradex, Savara is exploring other potential therapies that address various respiratory conditions, underscoring its commitment to respiratory health. The company is headquartered in Austin, Texas, and is publicly traded on the NASDAQ under the ticker SVRA. With a strong pipeline and a focus on scientific innovation, Savara aims to make significant contributions to the field of respiratory medicine and improve patient outcomes.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Austin, Texas, USA",
    "founded": "2017",
    "website": "https://www.savarapharma.com",
    "ceo": "Savara is managed by a team of experienced professionals in the biopharmaceutical industry.",
    "social_media": {
        "twitter": "https://twitter.com/SavaraPharma",
        "linkedin": "https://www.linkedin.com/company/savara-pharma/"
    },
    "investor_relations": "https://investors.savarapharma.com",
    "key_executives": [
        {
            "name": "Robbie E. L. B. Reitz",
            "position": "CEO"
        },
        {
            "name": "Seth K. H. S. S. Zuckerman",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Molgradex"
            ]
        }
    ],
    "seo": {
        "meta_title": "Savara Inc. | Innovative Therapies for Rare Respiratory Diseases",
        "meta_description": "Learn about Savara Inc., a biopharmaceutical company developing inhaled therapies for rare respiratory diseases. Discover their lead product, Molgradex, and their commitment to improving patient outcomes.",
        "keywords": [
            "Savara",
            "Biopharmaceuticals",
            "Rare Diseases",
            "Respiratory Health",
            "Molgradex"
        ]
    },
    "faq": [
        {
            "question": "What is Savara known for?",
            "answer": "Savara is known for developing innovative inhaled therapies for rare respiratory diseases."
        },
        {
            "question": "What is the lead product of Savara?",
            "answer": "The lead product of Savara is Molgradex, which is being developed for the treatment of pulmonary alveolar proteinosis."
        },
        {
            "question": "Where is Savara headquartered?",
            "answer": "Savara is headquartered in Austin, Texas, USA."
        },
        {
            "question": "When was Savara founded?",
            "answer": "Savara was founded in 2017."
        }
    ],
    "competitors": [
        "VRTX",
        "ALNY",
        "BMRN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BIIB",
        "REGN"
    ]
}